Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

aflibercept MeSH Supplementary Concept Data 2025


MeSH Supplementary
aflibercept
Unique ID
C533178
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C533178
Entry Term(s)
AVE 0005
AVE 005
AVE-0005
AVE-005
AVE0005
AVE005
VEGF Trap - regeneron
VEGF Trap-Eye
VEGF-Trap
ZIV-aflibercept
Zaltrap
eylea
Pharm Action
Angiogenesis Inhibitors
Registry Numbers
15C2VL427D
0
Heading Mapped to
*Recombinant Fusion Proteins
*Receptors, Vascular Endothelial Growth Factor
Frequency
1869
Note
has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders
Source
Drugs R D 2008;9(4):261-9
Date of Entry
2008/11/27
Revision Date
2021/01/12
aflibercept Preferred
AVE 005 Narrower
AVE 0005 Narrower
eylea Narrower
ZIV-aflibercept Narrower
Zaltrap Narrower
page delivered in 0.004s